Exploring a New Path for Patients with CKD
At Pathalys, we are committed to supporting the unique needs of patients through the development of therapeutics that may improve the management of chronic kidney disease (CKD).
Patients are already managing the demands of CKD – SHPT adds complexity.
People with CKD on hemodialysis manage a life organized around their condition. Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease in patients receiving dialysis, developing as the body struggles to maintain healthy calcium, phosphorus and parathyroid hormone levels when kidney function is lost.


We aim to help address the complexities of uncontrolled SHPT.
Pathalys is developing a new calcimimetic that may give clinicians a new tool to help manage SHPT.


The Latest News

Dialysis patients deserve more options.
At Pathalys, we are drawn to the challenges of CKD, not because they are easy, but because every patient deserves access to innovation and opportunity.